馃毃 #REVIEW 馃毃View quoted post on X
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
馃摉 馃憞
dlvr.鈥媔t/TW72Ll
Daniel Castellano
Verified account This account is verified. Learn more@cdanicas
Medical Oncologist. Hospital Univ. 12 de Octubre. Madrid. UCM. Head GU Unit. Executive Member @GUARDconsortitum
1.7K Following 3.9K Followers 9.5K Posts
Latest posts 5
馃幆 #ESMO26 Starting the Day with Excellent educational session of How to optimise care for pts receiving prostate cancer systemic therapy.
馃憠 @BarbaraJereczek nice presentation updating the management of HR-PC pts! 馃槉@OncoAlert @myESMO @APCCC_Lugano @urotoday @GuardConsortium
馃憠 @BarbaraJereczek nice presentation updating the management of HR-PC pts! 馃槉@OncoAlert @myESMO @APCCC_Lugano @urotoday @GuardConsortium
馃幆 #ESMO26 3潞 day Proffered paper GU non-prostate ca. Ph 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in mRCC.@montypal
馃憠 ORR 30%, CRS G3-4 6.0% with > ORR in> step-dose
@OncoAlert @myESMO @urotoday @DrYukselUrun @g_develasco @GuardConsortium @tompowles1
馃憠 ORR 30%, CRS G3-4 6.0% with > ORR in> step-dose
@OncoAlert @myESMO @urotoday @DrYukselUrun @g_develasco @GuardConsortium @tompowles1
馃幆 #ESMO2026 2潞 day Rapid oral GU non-prostate session. @Uro_Oncologist presented the HRQL of EV-304 periop MIBC!!
EV +pembro was not associated with a clinically meaningful detriment in general HRQoL or cystectomy-specific HRQoL!! @OncoAlert @myESMO @GuardConsortium @DrChoueiri @tompowles1 @urotoday @PGrivasMDPhD
EV +pembro was not associated with a clinically meaningful detriment in general HRQoL or cystectomy-specific HRQoL!! @OncoAlert @myESMO @GuardConsortium @DrChoueiri @tompowles1 @urotoday @PGrivasMDPhD
馃幆 #ESMO26 ctDNA analysis of EV304 study! ctDNA is strongly prognostic, regardless of therapy and ctDNA cleareance was >> with EVP!馃槉 @OncoAlert @myESMO @urotoday @UroTarget @GuardConsortium